A Special European Journal of Rheumatology Issue on Systemic Sclerosis: What and Why?

Overview

Journal Eur J Rheumatol

Publisher Aves

Specialty Rheumatology

Date 2020 Nov 9

PMID 33164730

Authors

Francesco Del Galdo

Marco Matucci-Cerinic

Affiliations

Soon will be listed here.

References

Abignano G, Del Galdo F . Biomarkers as an opportunity to stratify for outcome in systemic sclerosis. Eur J Rheumatol. 2020; 7(Suppl 3):S193-S202. PMC: 7647681. DOI: 10.5152/eurjrheum.2020.19065. View

Ota Y, Kuwana M . Endothelial cells and endothelial progenitor cells in the pathogenesis of systemic sclerosis. Eur J Rheumatol. 2020; 7(Suppl 3):S139-S146. PMC: 7647677. DOI: 10.5152/eurjrheum.2019.19158. View

Denton C, Yee P, Ong V . News and failures from recent treatment trials in systemic sclerosis. Eur J Rheumatol. 2020; 7(Suppl 3):S242-S248. PMC: 7647678. DOI: 10.5152/eurjrheum.2020.19187. View

Rosa I, Romano E, Fioretto B, Manetti M . The contribution of mesenchymal transitions to the pathogenesis of systemic sclerosis. Eur J Rheumatol. 2020; 7(Suppl 3):S157-S164. PMC: 7647682. DOI: 10.5152/eurjrheum.2019.19081. View

Herrick A, Dinsdale G, Murray A . New perspectives in the imaging of Raynaud's phenomenon. Eur J Rheumatol. 2020; 7(Suppl 3):S212-S221. PMC: 7647685. DOI: 10.5152/eurjrheum.2020.19124. View

Johnson S, van den Hoogen F, Devakandan K, Matucci-Cerinic M, Pope J . Systemic sclerosis: To subset or not to subset, that is the question. Eur J Rheumatol. 2020; 7(Suppl 3):S222-S227. PMC: 7647684. DOI: 10.5152/eurjrheum.2020.19116. View

Bruni C, Furst D . The burning question: To use or not to use cyclophosphamide in systemic sclerosis. Eur J Rheumatol. 2020; 7(Suppl 3):S237-S241. PMC: 7647679. DOI: 10.5152/eurjrheum.2020.19104. View

Brown Z, Nikpour M . Screening for pulmonary arterial hypertension in systemic sclerosis: Now or never!. Eur J Rheumatol. 2020; 7(Suppl 3):S187-S192. PMC: 7647680. DOI: 10.5152/eurjrheum.2020.19114. View

Mehta B, Espinoza M, Hinchcliff M, Whitfield M . Molecular "omic" signatures in systemic sclerosis. Eur J Rheumatol. 2020; 7(Suppl 3):S173-S180. PMC: 7647683. DOI: 10.5152/eurjrheum.2020.19192. View

10.

Ramahi A, Altorok N, Kahaleh B . Epigenetics and systemic sclerosis: An answer to disease onset and evolution?. Eur J Rheumatol. 2020; 7(Suppl 3):S147-S156. PMC: 7647676. DOI: 10.5152/eurjrheum.2020.19112. View

11.

Benfaremo D, Svegliati Baroni S, Manfredi L, Moroncini G, Gabrielli A . Putative functional pathogenic autoantibodies in systemic sclerosis. Eur J Rheumatol. 2020; 7(Suppl 3):S181-S186. PMC: 7647689. DOI: 10.5152/eurjrheum.2020.19131. View

12.

Volkmann E, Hoffmann-Vold A . Gastrointestinal tract microbiota modifications in systemic sclerosis. Eur J Rheumatol. 2020; 7(Suppl 3):S228-S236. PMC: 7647687. DOI: 10.5152/eurjrheum.2019.19103. View

13.

Mavrogeni S, Buch M, Markousis-Mavrogenis G, Dumitru B, Pugliese N, Gargani L . The perpetual sword of Damocles: Cardiac involvement in systemic sclerosis and the role of non-invasive imaging modalities in medical decision making. Eur J Rheumatol. 2020; 7(Suppl 3):S203-S211. PMC: 7647675. DOI: 10.5152/eurjrheum.2020.19110. View

14.

Frommer K, Neumann E, Muller-Ladner U . Role of adipokines in systemic sclerosis pathogenesis. Eur J Rheumatol. 2020; 7(Suppl 3):S165-S172. PMC: 7647688. DOI: 10.5152/eurjrheum.2020.19107. View